| Univariate analysis | Multivariate analysis |
---|
Factorsb
| p | HR (95%CI)c
| p | HR (95%CI) |
---|
EGF
| 0.008 | 1.635 (1.139–2.348) | 0.002 | 1.776 (1.233–2.559) |
HBEGF
| 0.034 | 1.477 (1.031–2.116) | 0.32 | 1.218 (0.828–1.793) |
TGFA
| 0.20 | 1.583 (0.882–1.806) |  |  |
AREG
| 0.002 | 1.759 (1.227–2.522) | 0.001 | 1.857 (1.257–2.743) |
BTC
| 0.006 | 1.662 (1.157–2.386) | 0.002 | 1.778 (1.233–2.564) |
EPGN
| 0.23 | 0.802 (0.562–1.145) |  |  |
EREG
| 0.28 | 1.218 (0.852–1.757) |  |  |
-
aLog-rank test was used in univariate analysis and Cox Regression method was used in multivariate analysis
-
bmRNA expression levels were measured as fragments per kilobase per million mapped reads (FPKM) and median mRNA expression levels were used as discriminators (epidermal growth factor (EGF): 17.88 FPKM; heparin-binding EGF-like growth factor (HB-EGF): 1274 FPKM; transforming growth factor-α (TGFA): 1695 FPKM; amphiregulin (AREG): 658 FPKM; beta-cellulin (BTC): 4 FPKM; epigen (EPGN): 32.5 FPKM; epiregulin (EREG): 350 FPKM), and the groups of patients with lower expression levels were set as reference
-
cHR, Hazard ratio. 95Â % CI, 95Â % confidence interval